Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients

Camillo Porta, Chiara Paglino, Ilaria Imarisio, Carlo Ganini, Lucia Sacchi, Silvana Quaglini, Vania Giunta, Mara De Amici

Research output: Contribution to journalArticle

Abstract

Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic cytokines other than VEGF, we measured the circulating levels of three pro-angiogenic cytokines: basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin (IL)-6. Methods: Cytokines were measured at baseline and on the first day of each treatment cycle until progression in 85 advanced kidney cancer patients treated with sunitinib using a quantitative sandwich enzyme immunoassay (ELISA) technique. Results: Even though no statistically significant differences in the titers of the three cytokines were observed between baseline and the time of progression in the whole patient cohort, in 45.3, 46.6, and 37.3% of the patients a more than 50% increase between baseline and the time of progression was shown in circulating IL-6, bFGF, and HGF, respectively. Furthermore, this increase was more than 100% in 37.3, 44, and 30.6% of the patients, respectively. We also demonstrated that, in these patients, cytokines tended to increase and to remain high immediately before progression. Conclusions: In a large percentage of kidney cancer patients, progression is preceded by a significant increase in pro-angiogenic cytokines other than VEGF.

Original languageEnglish
Pages (from-to)115-122
Number of pages8
JournalOncology
Volume84
Issue number2
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Cytokines
Hepatocyte Growth Factor
Kidney Neoplasms
Fibroblast Growth Factor 2
Therapeutics
Interleukin-6
sunitinib
Immunoenzyme Techniques
Enzyme-Linked Immunosorbent Assay

Keywords

  • Basic fibroblast growth factor
  • Hepatocyte growth factor
  • Interleukin-6
  • Kidney cancer
  • Progression
  • Sunitinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. / Porta, Camillo; Paglino, Chiara; Imarisio, Ilaria; Ganini, Carlo; Sacchi, Lucia; Quaglini, Silvana; Giunta, Vania; De Amici, Mara.

In: Oncology, Vol. 84, No. 2, 12.2012, p. 115-122.

Research output: Contribution to journalArticle

@article{6848213e3f9b41bbb068863eace081dd,
title = "Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients",
abstract = "Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic cytokines other than VEGF, we measured the circulating levels of three pro-angiogenic cytokines: basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin (IL)-6. Methods: Cytokines were measured at baseline and on the first day of each treatment cycle until progression in 85 advanced kidney cancer patients treated with sunitinib using a quantitative sandwich enzyme immunoassay (ELISA) technique. Results: Even though no statistically significant differences in the titers of the three cytokines were observed between baseline and the time of progression in the whole patient cohort, in 45.3, 46.6, and 37.3{\%} of the patients a more than 50{\%} increase between baseline and the time of progression was shown in circulating IL-6, bFGF, and HGF, respectively. Furthermore, this increase was more than 100{\%} in 37.3, 44, and 30.6{\%} of the patients, respectively. We also demonstrated that, in these patients, cytokines tended to increase and to remain high immediately before progression. Conclusions: In a large percentage of kidney cancer patients, progression is preceded by a significant increase in pro-angiogenic cytokines other than VEGF.",
keywords = "Basic fibroblast growth factor, Hepatocyte growth factor, Interleukin-6, Kidney cancer, Progression, Sunitinib",
author = "Camillo Porta and Chiara Paglino and Ilaria Imarisio and Carlo Ganini and Lucia Sacchi and Silvana Quaglini and Vania Giunta and {De Amici}, Mara",
year = "2012",
month = "12",
doi = "10.1159/000342099",
language = "English",
volume = "84",
pages = "115--122",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients

AU - Porta, Camillo

AU - Paglino, Chiara

AU - Imarisio, Ilaria

AU - Ganini, Carlo

AU - Sacchi, Lucia

AU - Quaglini, Silvana

AU - Giunta, Vania

AU - De Amici, Mara

PY - 2012/12

Y1 - 2012/12

N2 - Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic cytokines other than VEGF, we measured the circulating levels of three pro-angiogenic cytokines: basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin (IL)-6. Methods: Cytokines were measured at baseline and on the first day of each treatment cycle until progression in 85 advanced kidney cancer patients treated with sunitinib using a quantitative sandwich enzyme immunoassay (ELISA) technique. Results: Even though no statistically significant differences in the titers of the three cytokines were observed between baseline and the time of progression in the whole patient cohort, in 45.3, 46.6, and 37.3% of the patients a more than 50% increase between baseline and the time of progression was shown in circulating IL-6, bFGF, and HGF, respectively. Furthermore, this increase was more than 100% in 37.3, 44, and 30.6% of the patients, respectively. We also demonstrated that, in these patients, cytokines tended to increase and to remain high immediately before progression. Conclusions: In a large percentage of kidney cancer patients, progression is preceded by a significant increase in pro-angiogenic cytokines other than VEGF.

AB - Objectives: This study included a cohort of advanced renal cell carcinoma patients treated with sunitinib. Since resistance to sunitinib may be mediated through angiogenic cytokines other than VEGF, we measured the circulating levels of three pro-angiogenic cytokines: basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin (IL)-6. Methods: Cytokines were measured at baseline and on the first day of each treatment cycle until progression in 85 advanced kidney cancer patients treated with sunitinib using a quantitative sandwich enzyme immunoassay (ELISA) technique. Results: Even though no statistically significant differences in the titers of the three cytokines were observed between baseline and the time of progression in the whole patient cohort, in 45.3, 46.6, and 37.3% of the patients a more than 50% increase between baseline and the time of progression was shown in circulating IL-6, bFGF, and HGF, respectively. Furthermore, this increase was more than 100% in 37.3, 44, and 30.6% of the patients, respectively. We also demonstrated that, in these patients, cytokines tended to increase and to remain high immediately before progression. Conclusions: In a large percentage of kidney cancer patients, progression is preceded by a significant increase in pro-angiogenic cytokines other than VEGF.

KW - Basic fibroblast growth factor

KW - Hepatocyte growth factor

KW - Interleukin-6

KW - Kidney cancer

KW - Progression

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84868712956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868712956&partnerID=8YFLogxK

U2 - 10.1159/000342099

DO - 10.1159/000342099

M3 - Article

C2 - 23154434

AN - SCOPUS:84868712956

VL - 84

SP - 115

EP - 122

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -